Imagine trying to grow a specific type of medicine using a patient's own cells, but every patient's cells behave differently. This project creates a smart 'cooking' system for these cells that uses high-tech sensors to watch the process in real-time. It's like having a smart oven that automatically adjusts the temperature and time based on exactly how the cake is rising, ensuring a perfect result every time.
Manufacturing personalized cell therapies for solid tumors is currently too slow, inconsistent, and expensive, creating a bottleneck for clinical adoption.
A prototype smart bioprocessing platform featuring in-line fluorescence spectroscopy sensors and adaptive process control systems.
If you are a cell therapy developer dealing with high batch failure rates in solid tumor treatments — this project developed a smart bioprocessing platform that uses real-time sensors to ensure consistent product quality.
If you are a bioreactor manufacturer dealing with a lack of adaptive control systems for personalized medicine — this project developed fluorescence spectroscopy sensors that enable automated, real-time monitoring of cell expansion.
If you are a clinic dealing with long wait times for patients to receive their cells back — this project developed a platform that shortens the vein-to-vein manufacturing cycle time.
Based on available project data, the SMARTER platform is designed to reduce overall costs-of-goods (COGS) by improving production efficiency.
The project is currently building a prototype R&D platform which will serve as the basis for follow-up development of a commercial scale bioreactor in a GMP environment.
Based on available project data, the project exploits breakthrough discoveries in T cell expansion biomarkers and new fluorescence spectroscopy sensors, though specific licensing terms are not listed.
The technology aims to shorten manufacturing cycle times, which directly reduces the 'vein-to-vein' time for patients receiving therapy.
It uses in-line process analytical technologies and smart process control systems to enable adaptive control of the TIL biomanufacturing process.
The consortium is a lean 4-partner group across 3 countries (DE, ES, UK). It features a strong commercial-academic bridge with a 25% industry ratio, including a clinical-stage company (Achilles Therapeutics) and a specialized center of excellence (Cell and Gene Therapy Catapult), ensuring the research is aligned with GMP manufacturing requirements.
Contact the Gottfried Wilhelm Leibniz Universitat Hannover
Contact us to explore licensing opportunities for the SMARTER sensor technology.
